Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from HC Surgical Specialists Ltd ( (SG:1B1) ) is now available.
HC Surgical Specialists reported revenue of S$9.78 million for the six months ended 30 November 2025, slightly down 1.6% year-on-year, while profit attributable to shareholders rose 17.5% to S$3.97 million and earnings per share increased to 2.59 Singapore cents. The stronger bottom line was driven mainly by non-operational gains, including a higher fair value gain on financial assets at fair value through profit or loss and the absence of prior-year fair value losses on derivative financial instruments and losses from deemed disposal in an associate, and the board declared an interim dividend of S$0.009 per ordinary share, underscoring continued shareholder returns despite flat operating performance.
The most recent analyst rating on (SG:1B1) stock is a Buy with a S$0.50 price target. To see the full list of analyst forecasts on HC Surgical Specialists Ltd stock, see the SG:1B1 Stock Forecast page.
More about HC Surgical Specialists Ltd
HC Surgical Specialists Limited is a Catalist-listed healthcare group in Singapore that operates in the medical and surgical services industry. The company, together with its subsidiaries, focuses on providing specialist surgical care, particularly in the local Singapore market.
Average Trading Volume: 44,981
Technical Sentiment Signal: Buy
Current Market Cap: S$55.37M
Learn more about 1B1 stock on TipRanks’ Stock Analysis page.